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Early detection, classification and prognosis of human cancers by analysis of CpG methylation carry huge diagnostic potential.
MethCancerDB collects and annotates genes and sequences from the abundance of published methylation studies and interlinks
them to all methylation-relevant bioinformatical resources. MethCancerDB starts with 4720 entries from 348 sources and is freely
accessible at http://www.methcancerdb.net.
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Cytosine-5 DNA methylation epigenetically regulates gene activity
in humans. Methylation occurs in CpG dinucleotides, which are
relatively rare in the genome. Short stretches of DNA enriched in
CpG nucleotides are termed CpG islands. About 88% of all human
genes have such a CpG island in their promoter region (Kim et al,
2005). Hypomethylation is usually associated with gene activation
and hypermethylation with gene repression or silencing. Aberrant
DNA methylation at CpGs is crucial for developmental processes
as well as a range of human diseases like imprinting disorders and
cancer (Robertson, 2005). Methylation is maintained through
mitosis and is also stable in free DNA of body fluids (e.g., plasma),
making it a desirable biomarker. Detecting aberrant methylation is
a promising approach for early diagnosis, classification and
prognosis of cancer, and many studies have focused on this issue
in the past years (Laird, 2003). However, these studies are spread
throughout numerous journals. So far, two databases exist to assist
researchers in assay design: MethDB (Amoreira et al, 2003) and
MethPrimerDB (Pattyn et al, 2006). MethDB provides an overview
of methylation evidence across more than 40 species; MethPri-
merDB holds validated primer sequences and assay information on
four major PCR methods used in CpG methylation analysis. A
third database, called MethyCancer, will be published in 2008 and
combines different major databases as well as CpC island
sequencing data from the Chinese Cancer Genome/Epigenome
Project (He et al, 2008).
METHODS
Annotation of the database entries
The diversity of data types and analytical methods combined
with the fact that virtually all reports are paperbound made
the assembly of MethCancerDB challenging. In total, we could
allocate 4720 annotable entries from 4919 collected records,
originating from 2240 different genes. Entries are gene-centred
(instead of being sample- or study-centred). To cover all genes
relevant to CpG methylation in cancer, we also included a list
of census cancer genes (i.e., mutated genes causally implicated
in oncogenesis) (Futreal et al, 2004) and imprinted genes as well
as several review reports of methylated genes. Such sources
are collectively marked as ‘secondary source’ to indicate that
these are not original observations of aberrant methylation in
cancer.
We implemented an annotation pipeline to extend the initial
information of the entries. The gene identifier is sent to CGAP
Batch Gene Finder (Strausberg, 2001) to obtain various levels of
biological information, in particular, the official gene symbol (Eyre
et al, 2006), the UniGeneID and the corresponding sequence IDs
(e.g., RefSeqIDs). Then, all sequence IDs are annotated to their
chromosomal position using the UCSC Genome Browser (Kent
et al, 2002). CpG island information is crucial for tumour
suppressor hypermethylation analysis. All CpG islands within
10kb of the 50 end of the sequence are located and their upstream
(u) or downstream (d) position according to the 50 ends is
determined. Finally, sequences and general information of the CpG
islands are transferred from UCSC to the MethCancerDB.
Additionally, a ‘gene count’ sums up gene identifiers with the
same EntrezGeneID (or the same UniGeneID for database entries
without an EntrezGeneID). The gene count routine is executed for
each new entry. If a gene occurs repeatedly in a single source
(e.g., microarray profiling), the gene count increases only by one.
The gene count does not increase when the entry is derived from a
‘secondary source’.
RESULTS
Web interface
The database section ‘explore’ includes the search functions of
MethCancerDB. In our database, genes with their corresponding
promoter CpG islands can be filtered, browsed, selected and
downloaded. MethCancerDB supports searching for a combination
of the following terms: source, gene symbol, cancer type,
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smethylation status, study size, tissue type, method, sequence type,
gene count and study type. Entries can be selected/deselected and
downloaded by the ‘extract table’ function as tab-delimited files.
The entire database can also be downloaded. To allow interaction
of this database with other prominent resources, hyperlinks to
PubMed, CGAP Gene info (including NCBI Gene information like
Entrez Gene, UniGene, OMIM link, gene expression data, Gene
Ontology terms, similar sequences and homologues) and to the
three methylation-related databases, namely MethDB, MethPri-
merDB and MethyCancer, are provided. Furthermore, the 50UTR
gene start site (±10kb) of each SequenceID is hyperlinked to the
UCSC browser and the chromosomal coordinates displayed in the
database. In addition, all CpG islands from this region are listed
with their relative downstream or upstream position to the
SequenceID’s 50 end. Hyperlinks to meta-information and
sequences of the CpG islands, as obtained by the pipeline, are
provided.
Submission of novel entries can be done in the ‘submit’ section
after registration and log-in. In the simplest case, a submission can
contain as little information as a unique gene identifier (i.e., gene
symbol, GenBank accession, Protein accession, UniProt accessions,
UniGene ID or GeneID) and a PubMed ID (or alternatively an
URL; all URLs are considered as ‘secondary source’). Further
information is highly desired but not obligatory and can be
selected from the respective menus. Selectable cancer types are
derived from Jemal et al (2007). More complex submissions, which
could include various sequence types, significance reports and
personal comments, can be done by uploading a tabular data. A
corresponding template and additional guidelines are provided in
the ‘submit’ section. We then encourage submitters to provide
information about the significance of the methylated gene for the
investigated cancer phenotype (i.e., P-value, number of positive
patients). New entries are automatically annotated and integrated
into MethCancerDB using the pipeline described above. In the first
release, only gene identifiers, but not the sequences, are annotated.
In future, MethCancerDB will also store methylation information
of intergenic sequences and not-annotated transcripts. An
annotation pipeline for all sequences, including those already
recorded in the database, is planned.
The section ‘match’ is an opportunity for researchers who wish
to obtain methylation-relevant information for their genes but do
not want to submit to the database. This might be the case, when a
researcher obtained candidate genes for a malignancy from a large
high-throughput study, like genome, transcriptome or proteome
analyses, and is interested to know whether the resulting candidate
genes are also aberrantly methylated. The list of candidate genes
has to be uploaded as a txt file and information retrieval is done
using the pipeline described above (also including the gene count).
This information can be downloaded and is not saved to the
database.
Quality assurance and availability
MethCancerDB cannot be comprehensive without further submis-
sions by the scientific community. Data in the initial release were
extracted from PubMed by the authors; a senior biologist collected
studies and another biologist integrated its entries into the
database. A third biologist performed spot checks on the data.
All changes to the database are monitored and dated. The database
is updated after every new UniGene Build. Incorrect entries can be
reported by e-mail using the entry’s ID. All data of MethCancerDB
are freely available.
DISCUSSION
MethCancerDB provides a summary of pre-existing information
regarding DNA methylation in various malignancies. A novelty of
MethCancerDB is that its entries are based on entire studies
instead of single patients/observations. In contrast to MethDB,
MethPrimerDB and MethyCancer, in MethCancerDB, the experi-
mental design (e.g., study size, type of cancer, method, etc.) is
documented. Therefore, researchers can quickly overview all
studies and their results for a specific clinical/biological scenario.
Gene and CpG island information can be downloaded for the
appropriate genes. Validated assays for a gene are indicated by
links to the MethPrimerDB.
Annotating the genes to UniGene clusters makes it easier to
compare the methylation status of different genes as opposed to
comparing them on the basis of the original terms from PubMed
articles. A candidate gene identified in any biological screen can be
searched for a putative role in aberrant CpG methylation. This
might be more important in the future as integrative approaches
are gaining interest.
Completely independent from our database, bioinformaticians
from the Chinese Cancer Genome/Epigenome Project developed a
database, called MethyCancer, that integrates major databases
dealing with either methylation, CpG island prediction or the
cancer genome to a single display on the chromosomal level, called
MethyView. MethyCancer will be published in January 2008 and is
aimed at the beginning of DNA methylation research, whereas
MethCancerDB collects the evidence from finished research and
clinical studies. To strengthen the interaction between the
databases, MethyView was connected to the MethCancerDB genes.
In this way, the databases benefit from each other.
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